《大行》大和降金斯瑞生物科技(01548.HK)目标价至21元 续予“买入”评级

阿斯达克财经
Mar 18

大和发表研究报告指,金斯瑞生物科技(01548.HK) 去年业绩符合预期,销售额按年增61%至9.6亿美元,符合该行预测的9.61亿美元;经调整净利润升285%至2.3亿美元。至于今年指引,金斯瑞生物科技料Genscript Life Science(LSG)收入按年增长15至18%,经调整毛行率约为52%;经调整经营溢利约19%。另预计ProBio收入增长20至25%,并在2027年录得正...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10